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Introduction
Somatostatin is a neuropeptide hormone that is widely
distributed throughout the body. It was first discovered
as a factor inhibiting the release of growth hormone.
Later it was shown to have many functions in the
endocrine system including the inhibition of secretion
of other pituitary hormones, in addition to that of
gastrointestinal hormones. Moreover, somatostatin acts
as a neurotransmitter in the nervous system where it
also has generally inhibitory effects. Moreover, soma-
tostatin receptors (ssts) are detected in the immune
system, although the exact role of somatostatin in the
immune system remains elusive. A first step towards a
better understanding of the role of somatostatin in the
human immune system is to determine which cells
express somatostatin and its receptors.
Somatostatin exerts its effects through binding to a
family of five specific receptors, named sst1 to sst5. The
human genes for these receptors were cloned in 1992
and 1993 (1±4). The genes do not have introns.
However, for sst2 a spliced mRNA variant has been
identified (5, 6) and is named sst2B, whereas the
unspliced variant is designated sst2A. After ligand
binding the ssts transduce their actions into the cell
via coupling to G-proteins (7).
Somatostatin is secreted in two biologically active
forms: a 14 amino acid peptide (somatostatin-14)
and a 28 amino acid peptide (somatostatin-28). Both
forms bind with high affinity to all five receptor
subtypes. The widely used synthetic analogue,
octreotide, binds with high affinity only to sst
subtypes 2 and 5 and with lower affinity to receptor
subtype 3; binding to receptor subtypes 1 and 4 is
undetectable (8, 9). sst have been demonstrated in
both rodent and human immune cells (10, 11). In
this paper, some of the recent novel insights in the
expression and functional significance of ssts in
human immune cells are discussed.
Somatostatin binding sites on human
immune cells
Almost 20 years ago Bhathena et al. (12) demon-
strated the presence of somatostatin binding sites
on human peripheral blood mononuclear cells
(PBMC). Using radioisotope-labelled somatostatin
and Scatchard analysis, they showed that both
lymphocyte-enriched cell populations and monocyte-
enriched populations contained several hundred
binding sites per cell. Since then, somatostatin
binding sites have been demonstrated on several
immune and haematopoietic cells and tissues, by
means of various techniques. Radioligand binding
studies demonstrated ssts to be present on human
lymphoid and myeloma cell lines (13, 14). Using
radioligand binding as well as fluorescence-labelled
somatostatin and FACS analysis, somatostatin bind-
ing sites were detected on mitogen-activated human
peripheral lymphocytes (15). More than 95% of the
cells in all subpopulations studied (both B-lympho-
cytes and T-lymphocyte subsets) were labelled by
the fluorescent somatostatin derivative. In contrast,
our own studies using fluorescein-labelled somatos-
tatin failed to detect somatostatin binding sites on
both resting and mitogen-activated lymphocytes
(unpublished observations). On resting PBMC, red
blood cells and granulocytes no binding sites were
detectable by the radioligand assay (15). In the
same study, human leukaemic cells were shown to
contain somatostatin binding sites.
It is therefore a long established fact that human
immune cells can express ssts.
Localization of somatostatin binding
sites in human lymphoid tissues
sst expression can be detected in vivo by sst scinti-
graphy. After injection of radioisotope-labelled octreo-
tide, the ligand will bind to its receptors and,
subsequently, tissues with high densities of ssts (sst2,
sst5 and possibly also sst3) can be visualized with a
gamma-camera. This technique has been used exten-
sively to visualize neuroendocrine tumours (16). In
addition, several disorders of the immune system have
been shown to express such a high density of ssts that
they can also be visualized with this technique. These
disorders include malignant lymphomas (Hodgkin's
disease and non-Hodgkin lymphomas), granulomatous
diseases (tuberculosis, sarcoidosis, Wegener's granulo-
matosis) and other autoimmune diseases such as
rheumatoid arthritis (17±20). However, among normal
lymphoid tissues, only the spleen shows a high uptake
of labelled octreotide; the thymus or lymph nodes are
not visualized (21).
By means of somatostatin autoradiography (bind-
ing of radioisotope-labelled somatostatin or octreo-
tide to tissue sections), the presence of ssts in the
different areas of lymphoid tissues can be visua-
lized.
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Work by Reubi et al. (21, 22) demonstrated the
presence of ssts in normal human lymphoid tissues,
including gut-associated lymphoid tissue, thymus,
spleen and lymph nodes. Moreover, in addition to ssts,
several other peptide receptors, were localized in
distinct compartments of the immune tissues (22,
23). SSTs were localized mainly in the germinal centres
of lymphoid follicles, and more diffusely in the red pulp
of the spleen and in the medulla of the thymus.
Thus not only do immune cells in the peripheral
blood express ssts, but ssts are also present in normal
lymphoid tissues. Moreover, the sites of the lesions in
several haematological malignancies or immune-
mediated diseases also show sst expression.
Which sst subtypes are expressed in the
human immune system?
The fact that there are (at least) five different subtypes
of ssts and the possibility that these subtypes might
serve different (but probably overlapping) functions
raise the question as to which sst subtypes are
expressed in cells of the immune system. As somato-
statin binds to all five subtypes with high affinity and
octreotide and related synthetic analogues bind to three
subtypes with high or moderate affinity, binding studies
using these ligands are not informative as to which sst
subtype is expressed. RT-PCR is exceptionally well
suited to the examination of this problem, being a
very specific and very sensitive method for the detection
of RNA transcripts.
Unfortunately, different RT-PCR studies of sst subtype
expression in human immune cells have not provided
uniform results. sst subtype 2 was shown to be the
most prominently expressed subtype among leukaemia
cells and several lymphoid and myeloma cell lines (24).
However, the cell lines also expressed sst3 (all cell lines
except one) and several of the cell lines expressed sst4 or
sst5, or both, also. In the T-lymphoid cell line Jurkat, for
instance, mRNA of sst2, sst3, sst4 and sst5 was detected.
In the same study, human PBMC showed barely
detectable sst2 mRNAs, whereas this mRNA was
increased in Epstein Barr Virus (EBV)-transformed
lymphocytes and after phytohaemagglutinin (PHA)
stimulation of PBMC. Our own studies of several T-
and B-lymphoid cell lines showed only expression of
sst2 in four of 18 cell lines (25). This discrepancy can
probably be explained by differences in assay sensitivity.
Our recent studies applying a more sensitive RT-PCR
assay than before clearly detected sst2 and sst3 in the
Jurkat T-cell line and in EBV-transformed B-lymphocyte
cell lines (Table 1). In contrast with the findings
discussed above, is the report that the Jurkat T-cell line
expresses only sst subtype 3 (26). Finally, it was
recently found that human T-lymphocytes purified
from PBMC expressed only sst3, but that after mitogenic
activation with PHA they additionally expressed sst5
(27).
From this collection of data the strong impression
arises that immortalized cell lines are not representa-
tive of human immune cells in vivo, especially since
different clones from the same cell line (Jurkat) appear
to express different subtypes of the sst family. Moreover,
when comparing animal studies concerning sst subtype
expression in the immune system, care should be taken
when extrapolating to the human situation, as there
appear to be species-related differences. Rat PBMC,
spleen, thymus and lymph nodes were shown to
express sst3 and sst4 (28) whereas we found that
mouse PBMC, spleen and thymus express sst2 and sst4
mRNA. These findings are summarized in Table 2.
More intriguing are the divergent findings with ex vivo
human immune cells, which cannot be fully explained
from these data.
It also becomes apparent that it would be very
desirable to have some sort of quantitative measure-
ment of the amount of mRNA transcripts per cell (and
its relation with receptor numbers per cell) in order to
judge the biological relevance of the expressed receptor
subtypes. It should be kept in mind that, when one is
isolating RNA from 106 cells and performing a sensitive
RT-PCR that is able to detect 100 copies (or fewer) of
template in the assay, a positive signal could mean that
1 cell in 106 expresses 100 mRNA transcripts, or that
100 in 106 cells express just one single mRNA
transcript. Neither of these two extreme possibilities is
relevant for the cell population as a whole.
This last statement touches upon one of the major
drawbacks of the RT-PCR technique: it is not possible to
determine which cell types among a heterogenous cell
population express the SST subtypes detected. In order
to address this question, and considering the sensitivity
of the RT-PCR method, it is necessary to purify the cell
populations to a very high degree, for example using
magnetic beads coated with antibody specific for the
cell type to be studied. An alternative approach, today
feasible for sst1, sst2A and sst3, is to perform immuno-
histochemistry using specific antibodies directed
against the different sst subtypes.
Table 1 RT-PCR analysis of mRNA expression of somatostatin
(som) and somatostatin receptor subtypes in lymphoid cell lines.
sst1 sst2A sst3 sst4 sst5 som
T-cell lines
Peer 2 + + 2 2 2
HPB-ALL 2 + + 2 2 2
Jurkat 2 + + 2 2 2
B-cell lines
BLCL-APD 2 + + 2 2 2
BLCL-BSM 2 + + 2 2 2
BLCL-E091 2 + + 2 2 2
BLCL-EDN 2 + + 2 2 2
2, Absence and +, presence of mRNA as determined by RT-PCR.
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Which cell types express ssts?
Although the final answer to this question has not yet
been established, much has been learned from the
different approaches described above. Immune cells can
be classified according to the lineage along which they
have developed during haematopoiesis. The major
populations of immune cells found in the peripheral
blood can roughly be characterized as T-lymphocytes,
B-lymphocytes, monocytes and granulocytes. Each of
these cell-types differentiates into more specific subsets.
In addition, in the lymphoid organs many accessory
cell-types are found, such as epithelial cells, dendritic
cells, fibroblasts, nerve cells, endothelial cells and
muscle cells of blood vessels, making the question of
which cell type expresses ssts even more complex.
In the binding studies reviewed above, it was shown
that both lymphocyte- and monocyte-enriched cell
fractions from the peripheral blood possess ssts (12),
whereas granulocytes do not (15). Purified T-lympho-
cytes have been shown to express sst3 (27). In
agreement with these observations we recently found a
selective expression of sst3 receptors on enriched
populations of peripheral blood T- and B-cells, in
addition to the expression of sst2A receptors on activated
cells of the monocyte-macrophage lineage (unpublished
observations). Therefore we can deduce that T- and B-
lymphocytes and monocytes do express ssts.
In the autoradiographic studies described above, it
was found that germinal centres of lymphoid follicles
express ssts. Moreover, the sst-positive tissue compart-
ments did not co-localize with CD3-positive T-lympho-
cyte-rich compartments (23). In agreement with these
observations, CD3-positive cells in tissue biopsy speci-
mens from patients with rheumathoid arthritis or
granulomatous disease did not express sst2A receptors,
as determined by immunohistochemistry (see below).
Peripheral T-lymphocytes do express sst3 receptors, but
it remains to be established whether this receptor
subtype is expressed in T-lymphocytes present in
normal lymph nodes or in immune disease.
Effects of somatostatin on human
immune cells
Functional studies performed with sst-expressing
human immune cells provide further evidence for the
important role somatostatin may have in the human
immune system. Payan and coworkers showed in 1984
that somatostatin inhibits the incorporation of 3H-
thymidine into PHA-activated human T-lymphocytes
(29). However, other studies failed to detect any effect of
somatostatin on proliferation of either unstimulated or
PHA-activated human thymocytes (30).
Several studies investigated the effects of somatostatin on
cytokine production by human immune cells. Interferon-g
secretion by PHA-stimulated PBMC was inhibited,
although in one study only when non-physiological
concentrations somatostatin (1026 mol/l) were used
(31), whereas in another study the maximal effect was
observed between 1029 and 1028 mol/l (32). Natural killer
cell activity was inhibited by somatostatin, but inhibition
was only significant with high doses (33). Finally, in a
human T-cell line (Jurkat) somatostatin increased inter-
leukin-2 (IL-2) secretion and cell proliferation (26).
Immunoglobulin E (IgE) production by B-lympho-
cytes from atopic patients was inhibited by somato-
statin, but only when B-lymphocytes were cultured
together with T-lymphocytes and monocytes (34). This
latter observation suggests an indirect mode of action
of somatostatin on B-lymphocytes. In contrast, the
synthetic somatostatin analogue, octreotide, inhibited
pokeweed-mitogen-induced B-cell differentiation to
plasma cells in PBMC from normal human donors
(35). It is therefore not clear whether somatostatin
exerts a direct effect on human B-lymphocytes.
In human monocytes, opposing effects of somato-
statin have been described. Komorowski et al. (36)
reported that somatostatin stimulated the release of IL-
6 from lipopolysaccharide-activated, adherence-
selected, monocytes, whereas Peluso et al. (37) demon-
strated inhibition of IL-6 (and of TNFa and IL-1b) by
somatostatin. Monocyte activation, as measured by
HLA-DR expression and chemotaxis of neutrophils to
IL-8 produced by monocytes, was also reduced.
From these studies, it becomes clear that the actions
of somatostatin in the immune system can be very
diverse and are probably delicately regulated, as many
contradictory effects have been observed.
Detection of sst2A in human immune
diseases by immunohistochemistry
After reviewing the current knowledge on sst expres-
sion in normal human immune cells, we consider the
question of whether expression is altered in human
Table 2 RT-PCR analysis of mRNA expression of somatostatin
(som) and somatostatin receptor subtypes in normal rat and mouse
immune cells.
sst1 sst2A sst3 sst4 sst5 som
Rat
PBMC 2 2 + + 2 nd
Spleen + 2 + + 2 nd
Thymus 2 2 + + 2 nd
Lymph nodes 2 2 + + 2 nd
Mouse
PBMC 2 + 2 + 2 2
Spleen + 2 2 + 2 2
Thymus 2 + 2 + 2 2
Bone marrow 2 + 2 + 2 2
Data on rat SST subtypes are derived from ref. 34.
2, Absence and +, presence of mRNA as determined by RT-PCR;
nd = not determined.
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immune disease. Evidence that this is the case has been
provided by sst scintigraphy. In patients with active
rheumatoid arthritis, the affected joints could be visualized,
whereas after treatment the radioligand uptake in the joints
was significantly reduced. The amount of radioligand
uptake correlated with the swelling and painfulness of the
affected joints (19). Subsequent studies using an anti-sst2A
antibody in immunohistochemistry revealed that sst2A
receptors were expressed in biopsy specimens of synovia of
affected joints from patients with rheumatoid arthritis (38).
Receptors were present on endothelium of blood vessels and
on dispersed cells throughout the inflamed tissue. Double
staining with anti-sst2A and cell-type-specific antibodies
showed that sst subtype 2A receptors were expressed on
CD31-positive endothelial cells, and on CD14- or CD68-
positive monocytes and macrophages. sst2A receptors were
not expressed on CD3 positive T-lymphocytes.
In a similar way, it was shown that granulomas from
nine of 12 patients with sarcoidosis were positive when
stained with anti-sst2A (39). The three negative tissue
sections were highly fibrotic, with only a limited
mononuclear infiltrate. Again, the sst2A receptors
were demonstrated on macrophages and not on
T-lymphocytes.
It is therefore very likely that sst2A expressed on
monocyte-derived cells has an important role in
inflammation. Besides the earlier mentioned correla-
tion between inflammation and uptake of radiolabelled
octreotide in scintigraphy (19), it was also demon-
strated that somatostatin inhibits both proliferation of
synovial cells from patients with rheumatoid arthritis
and production of the pro-inflammatory cytokines IL-6
and IL-8 (40). Notably, these authors also report the
presence of sst1 and sst2 on fibroblast-like synovial cells
and the absence of receptors on T-lymphocytes. sst2
receptors were up-regulated when the synovial fibro-
blast-like cells were stimulated with TNFa. Moreover,
the fibroblast-like cells produced somatostatin, whereas
the synovium-infiltrating lymphocytes did not.
Pro-inflammatory cytokine production is necessary to
keep granulomas in sarcoidosis active. This cytokine
production possibly can be influenced by somatostatin.
In one of the aforementioned studies, it was shown that
pro-inflammatory cytokine production by monocytes is
inhibited by somatostatin, that monocyte activation is
reduced, and that chemotaxis of neutrophils towards the
activated monocytes is reduced (37). Whether somatos-
tatin is produced locally in human sarcoid granulomas is
not known. However, we speculate that sst2A receptors
on monocyte-derived cells in inflammatory diseases such
as rheumatoid arthritis and sarcoidosis are important
targets for somatostatin to modulate cytokine secretion
and therewith inflammation.
Conclusion
To summarize our current knowledge concerning sst
expression in human immune cells, we can conclude
that these receptors are expressed on normal human
immune cells in peripheral blood and in normal human
lymphoid tissue. Functional studies have demonstrated
that somatostatin may influence cell proliferation,
cytokine and immunoglobulin production and natural
killer activity, in addition to HLA-DR expression and
chemotactic activity of activated monocytes. sst subtypes
appear to be differentially expressed on specific cell
subsets of the human immune system. In immune-
mediated diseases, sst expression can be altered. Under-
standing the clinical significance of these findings
requires further studies.
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